Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02153723|
Recruitment Status : Completed
First Posted : June 3, 2014
Results First Posted : November 5, 2018
Last Update Posted : November 5, 2018
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Drug: Glatiramer Acetate
All participants were recruited between Aug 2014-Jan 2015, from the population treated at the Rett Center at Montefiore.
Of 11 screened subjects, 10 met the inclusion/exclusion criteria and completed the trial. One patient was excluded due to prolonged QTc.
Data analysis was performed after the first 10 participants completed the study.